The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

Stocks•8 May 2026•

1 min read

NYSE American Accepts Cryo-Cell International Compliance Plan to Maintain Listing

Key Facts

1Cryo-Cell International announced that NYSE American has accepted its plan to regain compliance with continued listing standards.

2The company was previously notified on March 12, 2026, that it was not in compliance with Section 1003 (a) of the NYSE American Company Guide.

Cryo-Cell International (CCEL) announced that NYSE American has formally accepted its plan to regain compliance with continued listing standards. The company was previously notified on March 12, 2026, regarding its failure to meet the requirements of Section 1003 (a) of the NYSE American Company Guide. With this acceptance, the company has been granted a remediation period to execute its strategic plan and avoid potential delisting. During this timeframe, the exchange will conduct periodic reviews to ensure the company is making sufficient progress toward meeting the standards. This development is viewed as a positive step for investors as it mitigates immediate delisting risks for the small-cap stock. Cryo-Cell's common stock will continue to be listed on the exchange while management works to address the identified deficiencies.